Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies
- 2.3k Downloads
Diarrhoea and constipation are common toxicities of chemotherapy, and both are poorly understood. They are manifestations of alimentary mucositis, a condition which affects the entire gastrointestinal tract.
The absolute percentage of patients that have diarrhoea or constipation as a result of their treatment has yet to be fully defined, although general estimates place 10% of patients with advanced cancer as being afflicted. Although there has been some major progress in recent years with understanding the mechanisms of oral and small intestinal mucositis, diarrhoea and constipation have received very little attention. Although diarrhoea is a well-recognised side-effect of both chemotherapy and radiotherapy, very little research has been conducted on the mechanisms behind diarrhoea or its treatment. Much of the information in the published literature is based on clinical observations with very little basic science existing. Constipation is not as well recognised and very little is known about its mechanisms.
This review will examine in detail the potentially complex pathogenesis of post-chemotherapy diarrhoea in both animal models and the clinical setting. Furthermore, it will explore what is known about chemotherapy-induced constipation. It will then outline an evidence-based pathway for the investigation and treatment of post-chemotherapy diarrhoea and constipation.
KeywordsDiarrhoea Constipation Mucositis Chemotherapy
- 2.Alimonti A, Satta F, Pavese I, Burattini E, Zoffoli V, Vecchione A (2003) Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer. Ann Oncol 14:805–806CrossRefPubMedGoogle Scholar
- 4.Araki E, Ishikawa M, Iigo M, Koide T, Itabashi M, Hoshi A (1993) Relationship between development of diarrhaea and the concentration of SN-38, and active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res 84:697–702PubMedGoogle Scholar
- 22.Gibson RJ, Keefe DMK, Clarke JM, Regester GO, Thompson FM, Goland GJ, Edwards BE, Cummins AG (2002) The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer. Cancer Chemother Pharmacol 50:53–58CrossRefPubMedGoogle Scholar
- 27.Gosselink MP, Schouten WR, van Lieshout LMC, Hop WCJ, Laman JD, Ruseler-van Embden JGH (2004) Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciproffloxacin in the treatment of pouchitis. Dis Colon Rectum 47:1519–1525CrossRefPubMedGoogle Scholar
- 28.Gutheil JC, Kearns CM (1997) Antimetabolites. In: Perry MC (ed) The chemotherapy source book. Williams & Wilkins, Baltimore, MD, pp 317–344Google Scholar
- 35.Jenkins D, Balsitis M, Gallivan S, Dixon MF, Gilmour HM, Shepherd NA, Theodossi A, Williams GT (1997) Guidelines for the initial biopsy diagnosis of suspected chronic idiopathic inflammatory bowel disease. Br Soc Gastroenterol Int J Clin Pathol 50:93–105Google Scholar
- 36.Keefe DMK (1998) The effect of cytotoxic chemotherapy on the mucosa of the small intestine. Department of Medicine, University of Adelaide, AdelaideGoogle Scholar
- 41.Klainer AS, Gorbach SL, Weinstein L (1967) Studies of intestinal microflora. VI: Effect of X irradiation on the fecal microflora of the rat. J Bacteriol 92:378–382Google Scholar
- 47.Macdonald DR (1997) Neurotoxicity of chemotherapeutic agents. In: Perry MC (ed) The chemotherapy source book. Williams & Wilkins, Baltimore, MD, pp 745–766Google Scholar
- 51.Milles SS, Muggia AL, Spiro HM (1962) Colonic histologic changes induced by 5-fluououracil. Gastroenterology 43:391–399Google Scholar
- 62.Shinohara H, Killion JJ, Kuniyasu H, Kumar R, Fidler IJ (1998) Prevention of intestinal toxic effects and intensification of Irinotecan’s therapeutic efficacy against murine colon cancer liver metastases by oral administration of the lipopeptide JBT 3002. Clin Cancer Res 4:2053–2063PubMedGoogle Scholar
- 63.Shinohara H, Killion JJ, Bucana CD, Yano S, Fidler IJ (1999) Oral administration of the immunomodulator JBT-3002 induces endogenous interleukin 15 in intestinal macrophages for protection against irinotecan-mediated destruction of intestinal epithelium. Clin Cancer Res 5:2148–2156PubMedGoogle Scholar
- 70.Sonis ST, Elting LS, Keefe DM, Peterson DE, Schubert MM, Hauer-Jenson M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein E (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100:1995–2025CrossRefPubMedGoogle Scholar
- 73.Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, Kamataki T (1996) Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 56:3752–3757PubMedGoogle Scholar
- 74.Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, Kamataki T (1998) Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats. Cancer Chemother Pharmacol 42:280–286CrossRefPubMedGoogle Scholar